Predicted to have ATP binding activity and protein serine/threonine kinase activity. Predicted to be involved in several processes, including histone-serine phosphorylation; positive regulation of histone modification; and regulation of transcription, DNA-templated. Predicted to localize to the cytoplasm and nucleoplasm. Orthologous to human RPS6KA5 (ribosomal protein S6 kinase A5); PARTICIPATES IN p38 MAPK signaling pathway; the extracellular signal-regulated Raf/Mek/Erk signaling pathway; mitogen activated protein kinase signaling pathway; INTERACTS WITH benzo[a]pyrene; bisphenol A; chloroprene.
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form]], Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form]
Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein, SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] more ...
[U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein], SB 203580 inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA
SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein], SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
